Last reviewed · How we verify
NCT06846385
Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis
Phase 2, PHASE3 trial testing Placebo in Seasonal Allergic Rhinitis in 160 participants. Currently enrolling.
31 May 2025
Quick facts
| Lead sponsor | Shanghai Mabgeek Biotech.Co.Ltd |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 20 March 2025 |
| Primary completion | 31 May 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Placebo
- MG-K10 Humanized Monoclonal Antibody Injection — full drug profile →
Conditions studied
- Seasonal Allergic Rhinitis — all drugs for Seasonal Allergic Rhinitis →
Sponsor
Shanghai Mabgeek Biotech.Co.Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Seasonal Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter, randomized, double-blind, placebo-controlled Phase II/III seamless clinical study evaluating the efficacy, safety, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, and immunogenicity of MG-K10 humanized monoclonal antibody injection in the treatment of seasonal allergic rhinitis
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chinese Position Paper on Biologic Therapy for Allergic Rhinitis.
Zhang Y, Li J, Li X, Wang M, et al · · 2026 · cited 1× · PMID 41872701 · DOI 10.1111/all.70312 -
Evaluating stapokibart in the treatment of seasonal allergic rhinitis.
Wang M, Li J, Zhang L, Zhang Y. · · 2025 · PMID 40900141 · DOI 10.1080/1750743x.2025.2554562
Verify or expand the search:
- PubMed search for NCT06846385
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Seasonal Allergic Rhinitis
Currently open trials in the same condition.
- NCT07055542 — Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study · NA · recruiting
- NCT07291284 — Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis · Phase 3 · active not recruiting
- NCT06300203 — Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis · Phase 2 · recruiting
- NCT04815668 — Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis · NA · recruiting
Other Shanghai Mabgeek Biotech.Co.Ltd trials
Trials by the same sponsor.
- NCT07103174 — A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis · Phase 2 · not yet recruiting
- NCT07054034 — Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects · Phase 2 · active not recruiting
- NCT06837922 — Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma · Phase 3 · recruiting
- NCT06026891 — Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis · Phase 3 · unknown
- NCT05659927 — Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06846385 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Mabgeek Biotech.Co.Ltd
- Last refreshed: 18 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06846385.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing